Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Induction Study in Ulcerative Colitis
NCT03398148Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2018
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 44
01
Overview
A Phase 3 trial of risankizumab in ulcerative colitis (UC), sponsored by AbbVie Inc.. Started Mar 2018; status: completed.
02
Drugs
risankizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03398148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398148.